EUVIMEDEUVIMED entdecken
Crossref

Exploring the preventive effect of sodium valproate on benign recurrent vertigo: A case series and literature review

Jun Cao iD, Liuliu Xiong iD, Runtao Zhang, Ruiqi Jia, Juanjuan Zhang, Yajuan Hu iD, Le Wu, Jingye Wang iD

Journal of Vestibular Research · 28.07.2026

DOI: 10.1177/09574271261473595 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Vestibular Research, online erschienen am 28.07.2026. Verfasst von Jun Cao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Die Arbeit nennt 35 Literaturangaben. Gefördert von: The Key Project of the Research Foundation of Anhui Institute of Translational Medicine, The Research Fund Project of Anhui Medical University, Health Research Program of Anhui.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Benign recurrent vertigo (BRV) accounts for a high proportion of episodic vestibular syndrome (EVS) patients. To date, randomized controlled trials and guidelines are lacking, and preventive treatment has not been established.

Objective

In clinical practice, we have found that sodium valproate has excellent effect on reducing vertigo attacks in BRV patients. Herein, these cases were collected and analyzed to share our clinical experience.

Methods

In this retrospective case series, we evaluated 84 patients with BRV or vestibular migraine (VM) who received prophylactic treatment with sodium valproate (400–500 mg/day) between April 2022 and July 2024. The primary clinical outcomes were the proportion of patients achieving a ≥50% reduction in monthly vertigo days (50% reduction rate) and the complete remission rate. Patients who achieved complete symptom resolution and subsequently discontinued medication were monitored to assess post-withdrawal recurrence rates.

Results

A total of 84 patients were enrolled, including 43 in the BRV group and 41 in the VM group. After 3 months of prophylactic treatment with sodium valproate, 91.1% of patients had a 50% reduction rate in monthly vertigo days and 71.4% had complete remission. There was no significant difference in preventive efficacy between the VM group and BRV group ( p = 0.348). There was no significant difference in the cumulative recurrence rates between different preventive treatment courses (

Schlagwörter

Stichwörter der Autor:innen

benign recurrent vertigopreventive treatmentsodium valproatevestibular migraine

Autor:innen und Institutionen

  • Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

ORCID-Profile: Jun Cao, Liuliu Xiong, Yajuan Hu, Jingye Wang

Förderung

  • The Key Project of the Research Foundation of Anhui Institute of Translational Medicine
  • The Research Fund Project of Anhui Medical University
  • Health Research Program of Anhui

Zitieren

APA

Cao, J., Xiong, L., Zhang, R., Jia, R., Zhang, J., Hu, Y., Wu, L., & Wang, J. (2026). Exploring the preventive effect of sodium valproate on benign recurrent vertigo: A case series and literature review. Journal of Vestibular Research. https://doi.org/10.1177/09574271261473595

Vancouver

Cao J, Xiong L, Zhang R, Jia R, Zhang J, Hu Y, et al. Exploring the preventive effect of sodium valproate on benign recurrent vertigo: A case series and literature review. Journal of Vestibular Research. 2026. doi:10.1177/09574271261473595

BibTeX
@article{Cao2026,
  author = {Cao, Jun and Xiong, Liuliu and Zhang, Runtao and Jia, Ruiqi and Zhang, Juanjuan and Hu, Yajuan and Wu, Le and Wang, Jingye},
  title = {Exploring the preventive effect of sodium valproate on benign recurrent vertigo: A case series and literature review},
  journal = {Journal of Vestibular Research},
  year = {2026},
  doi = {10.1177/09574271261473595}
}
Kostenlos starten →